Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumor DNA Minimal Residual Disease-guided Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer

NCT06157216 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.

NCT NCT06157216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06157216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumor DNA Minimal Residual Disease-guided Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer
Lead sponsor
Qilu Hospital of Shandong University
Phase
Not applicable
Overall status
Active, not recruiting
Start date
October 1, 2023
Completion date
April 1, 2029
Enrollment
65 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii-iii gastric cancer